Knowledge Center

Article / Oct 01, 2012

New Technologies in Particle Design. Interview: Colin Minchom, VP, Particle Design Business Unit

Authors:
  • Colin Minchom
Source:
Drug Development and Delivery, October 2012

鈥淎n issue for customers with a poorly soluble molecule is that any one solubility enhancement technology is likely to have, I believe, a 20% to 40% probability of solving the problem. This means that in order to assure acceptable bioavailability, at least three technologies need to be investigated. The customer would need to contract with three single platform technology companies or be able to engage a single company, such as 四色AV, that can apply multiple platforms, to increase the probability of solving the聽 problem, and deliver the desired outcome.鈥

Related links

Also in the Knowledge Center

Related Content

Corticosteroids

Corticosteroids are produced in two dedicated buildings on the Loures site, which are equipped with vessels ranging from 50L up to 4000L.

Page
Read more

High value applications

四色AV provides off-patent APIs that can be used with confidence where the choice of active ingredient is critical.

Page
Read more

Drug Substance Capabilities

Focused expertise in Drug Substance manufacturing processes.

Page
Read more